If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
I find it concerning that the narrative here is so
Blinkered, strong parallels with the closing days of many AIM stock of the past.
Just to be clear there are 3options not the 2options that Tommy is so keen to present.
1 - They have info and are deliberately witholding (Fanciful)
2 - They are not ready to divulge as they don’t have all the info yet ( this is the optimists view fingers crossed)
3 - They have nothing to say because sadly things are not progressing as they had hoped (a distinct possibility that cannot be ignored)
XEL had proven reserves of North Sea oil and a technique to extract they never made it. Yet in the final days it was their job not to admit this and to remain positive.
We have a drug that we are pretty confident works and a delivery method… It’s the boards job to attempt to commercialise it right until the end.
Mani - How are my posts defending the board?
I’m just explaining to you how the LTIPS work and pointing out that since 2020 the board have received zero earn out from the LTIPS and won’t unless something drastic happens to the share price.
Professional - No downside? The LTIP threshold is currently not met for any of the options granted after 2019. So they are not able to vest any of those options. Seems adequate downside non-performance therefore no options.
If the TSR was to exceed the comparative index it’s then a sliding scale to access those options.
Ref entrepreneurs I’d want them to make the calls based on their technical experience and not the calls based on their financial exposure. No one wants a rushed decision based on recovering their % outlay vs the bigger picture that might bring the bigger return down the road.
Professional - I really don't understand why people have issue with the options. They are not free they are performance based so will not exist unless targets are met.
As for really good entrepreneurs the smart ones never risk their own cash that's what PE is for.
A common sense approach to Risk management explains why the directors would be unwise to purchase shares.
If SNG is a success their PERFORMANCE based LTIPS will be triggered and they will make a lot of money, As will anyone invested.
If SNG is not a success their LTIPS won't get triggered. They will likely loose their jobs so investing their own capital is a very risky move considering the volatility of the sector and small biotech's in general.
Directors buying now would almost be a very desperate sign. The only rationale would be to try and prop a falling share price but it's pretty well bottomed out anyway.
Joe80 - I think it’s pretty clear and obvious from the communication from the company why they can’t declare a discovery.
The traditional OnG rules don’t apply to the play.
First they have to develop the methodology of how you quantify what they have or don’t have. That will need to be robustly supported by experts in scientific community before you’ll hear them claim a discovery.
Joey - Did you also see the study mapping ratios of ring finger to index finger length to likelihood of covid complications in males?
This ratio is linked to testosterone levels in the womb.
Interesting stuff.
Great video very clear and precise statements from Lorna.
The realisation of the uniqueness of the play type goes a long way to explaining why the evaluation will take longer than people may expect.
They are charting new territory.
All we can do is sit on our hands and wait for the analysis to drop.
This is a comfortable hold now for me.
Tommy - Agreed it’s awful.
But that begs the question why. They are not publicly listed so how do they get their funding. Etc etc.
Pull the threads you might surprise yourself.
Mani - It depends on your experiences. Personally their reputation got them traction with the NIH when it mattered at a time of national importance. To be one of the first across the line to launch a trial after the pandemic outbreak.
Investor made a lot of money during this period. I’m sorry if you were not one of them.
Tommy - It depends how you view the structure at Southampton and how much of that expertise is in-house and how much is the Southampton frame work they exist around.
As I noted previously Dragon officially launched with SNG as the partner this then got swapped out for Southampton Uni and Top Md.
Mani,
External work in related fields is to be expected and encouraged.
It elevates senior professional status in the industry forges strong partnerships and can foster innovation that can be brought back in-house.
I’m sure you are aware that SSH works as a professor as well as at SNG?
His career has spanned 55years really the chap deserves a restful retirement. But he is one of the great minds that will tireless contribute to the cause until he sadly can no longer.
Tommy - “Gene expression signatures from blood taken at the point of admission to hospital predicted ICU admission of treatment naïve patients with COVID-19.”
Next time you attend an AGM dig a bit into the data bank afterwards and you might start to find a few threads and also keep an eye out for some new patents in the next 6months out of Southampton linked outfits.
Tommy - Synairgen where originally listed on the dragon project only to be removed and replaced by TopMd. I forget that you where not invested here when that happened.
In the video that appears to have not linked properly. Bio markers linked to acute Covid 19 are discussed in relation to bio markers also linked to influenza and flu. It’s a substantial data set and highly relevant.
Perhaps the video links didn’t work?
2023 project Dragon conference I suggest you seek the lectures out. There is some very relevant data for SNG.
and since no one seems to have been keeping up to date with this.
https://m.youtube.com/watch?si=k87u0vcalwlp0rak&v=g8tqt19r1ka&feature=youtu.be
https://m.youtube.com/watch?v=e***sytflfq&list=plnlp17tbr51ibaccpzuzcmb9rcakwenuj&index=9
As I’ve said before https://www.topmd.co.uk/
They literally share a corridor.